Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) CEO Christopher Giordano purchased 6,000 shares of the business’s stock in a transaction on Friday, September 11th. The shares were purchased at an average price of $1.88 per share, with a total value of $11,280.00. Following the completion of the purchase, the chief executive officer owned 17,324 shares in the company, valued at approximately $32,569.12. This trade represents a 52.98% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Christopher Thomas Giordano also recently made the following trade(s):
- On Tuesday, September 15th, Christopher Giordano acquired 4,850 shares of Tenax Therapeutics stock. The stock was acquired at an average cost of $1.82 per share, for a total transaction of $8,827.00.
Tenax Therapeutics Trading Down 1.6%
NASDAQ TENX traded down $0.03 during trading hours on Tuesday, hitting $1.83. 1,641,507 shares of the company’s stock traded hands, compared to its average volume of 6,731,546. Tenax Therapeutics, Inc. has a 52 week low of $1.31 and a 52 week high of $19.40. The firm has a market capitalization of $68.48 million, a P/E ratio of -1.24 and a beta of 0.83. The business’s fifty day moving average price is $8.02 and its two-hundred day moving average price is $11.33.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Letko Brosseau & Associates Inc. purchased a new stake in Tenax Therapeutics in the 4th quarter worth $130,000. Bank of America Corp DE lifted its position in shares of Tenax Therapeutics by 391.2% in the first quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company’s stock valued at $297,000 after acquiring an additional 14,789 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Tenax Therapeutics by 21.5% in the first quarter. Renaissance Technologies LLC now owns 152,600 shares of the specialty pharmaceutical company’s stock worth $2,440,000 after acquiring an additional 27,021 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of Tenax Therapeutics in the first quarter worth about $501,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Tenax Therapeutics during the second quarter worth about $485,000. Institutional investors own 1.67% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on TENX shares. Chardan Capital cut Tenax Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a report on Tuesday, August 11th. Evercore cut Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target for the company. in a research report on Tuesday, August 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tenax Therapeutics in a research note on Thursday, September 10th. William Blair cut Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, August 10th. Finally, Canaccord Genuity Group set a $4.00 price objective on Tenax Therapeutics and gave the company a “buy” rating in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $14.00.
Get Our Latest Analysis on TENX
About Tenax Therapeutics
Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.
Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.
Read More
- Five stocks we like better than Tenax Therapeutics
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
